CAMBRIDGE, Mass., June 16, 2025 -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company, announced plans to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104, targeting first-line pancreatic cancer patients. The updates will be shared during a conference call and live webcast scheduled for June 17, 2025, at 8:00 am ET. The results of the trial will be presented during this event, and the webcast will be available in the Investor Relations section of Immuneering's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469059-en) on June 16, 2025, and is solely responsible for the information contained therein.